The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

EMA CHMP recommends approval of Opdivo + chemo for the neoadjuvant treatment of PD-L1 positive, resectable NSCLC at a high risk of recurrence

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The European Medicine Agency’s Committee for Medicinal Products for Human Use recommended the approval of Opdivo plus platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer at a high risk of recurrence in adult patients with tumor cell PD-L1 expression ≥1%. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP). 
By Lee Greenberger
Drugs & Targets

CHMP recommends approval of Opdivo + Yervoy for unresectable or advanced HCC

The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) from Bristol Myers Squibb for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma, based on results from the phase III CheckMate-9DW trial. The CHMP opinion will now be reviewed by the European Commission.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account